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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 9 0 1 – 9 0 6906in other areas. Although the health system continues to work to
gain broader physician support for the assessment process, the
organization as a whole supports the application of the value
concept in evaluating medications. These characteristics suggest
that the model could be scaled up for application in other areas.
The health system’s experience with the model to date is
limited. It does not yet have data on how its formulary decisions
have affected physicians’ approaches to treatment, patients’
behavior, the social and financial impact on patients, or the
financial impact on the institution. There was concern that
patients may transfer their care to another provider if a medica-
tion the health system deemed to be of relatively low value
was unavailable. Thus far this has not occurred, and patients
have not complained to the health system. As the health system
goes forward with its medication value model, it is desirableto incorporate patient-centric shared decision making into
the model.
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